Mas receptor signalling supports spermatogenesis and protection against diabetic testicular injury in mice
This study demonstrates that Mas receptor signaling is essential for normal spermatogenesis and that its pharmacological activation with AVE0991 offers partial protection against testicular injury and sperm dysfunction in a diabetic mouse model, although the underlying mechanism and receptor dependence in this context remain incompletely defined.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human body relies on a complex network of chemical signals to keep its systems running smoothly, much like a city needs a traffic control center to manage the flow of vehicles. In the realm of male reproduction, one such system is the renin–angiotensin system, a well-known network that typically regulates blood pressure and fluid balance. However, scientists have discovered that this same network exists within the male reproductive tract, where it plays a different, yet vital, role. At the heart of this local system is a specific receptor, a protein on the surface of cells that acts like a lock waiting for a key. When a molecule called angiotensin-(1–7) binds to this lock, known as the Mas receptor, it triggers a chain of events that supports the health and development of sperm. While we know that oxidative stress and metabolic issues like diabetes can damage the testes, it has remained unclear whether activating this specific receptor could help protect sperm production or repair damage caused by high blood sugar. Understanding this mechanism is crucial because male infertility is a growing global concern, and finding new ways to support sperm health could offer hope where current treatments fall short.
A team of researchers at Capital Medical University in Beijing set out to investigate whether this Mas receptor signaling is essential for making healthy sperm and if boosting it could shield the testes from the damage caused by diabetes. They approached the question from two angles: first by looking at human sperm samples, and second by conducting detailed experiments on mice. In the human portion of the study, the team collected samples from men with normal sperm movement and men with a condition called asthenozoospermia, where sperm move poorly. They found that in the men with poor sperm movement, the levels of the Mas receptor protein were significantly lower. Furthermore, when they looked at the genetic material inside the sperm, the instructions for building this receptor were also less abundant. This suggested a direct link between the presence of this receptor and the ability of sperm to swim effectively.
To test if this receptor was truly necessary for sperm production, the researchers turned to mice. They studied mice that had been genetically engineered to lack the gene for the Mas receptor entirely. These mice, along with normal mice treated with a drug that blocks the receptor, showed clear signs of reproductive trouble. Their testes had a disorganized structure, and the number of sperm they produced was reduced. This confirmed that the Mas receptor is not just a bystander but a necessary component for the normal development of sperm. The researchers then asked a more specific question: could activating this receptor help when the testes are under attack from diabetes? They induced diabetes in a group of mice using a chemical that damages the cells responsible for producing insulin, mimicking the high blood sugar seen in human type 1 diabetes. These diabetic mice naturally suffered from poor sperm quality and damaged testicular tissue.
The researchers then treated these diabetic mice with a drug called AVE0991, which is designed to mimic the action of the natural molecule that activates the Mas receptor. Over a period of six weeks, the treated mice showed a remarkable improvement. Their testicular tissue looked healthier, and the concentration and movement of their sperm increased compared to untreated diabetic mice. However, the treatment was not a complete cure; while it improved the physical structure of the testes and the sperm count, it did not fully restore the specific chemical signaling pathways inside the cells that are usually involved in cell survival. Crucially, when the researchers tried to give this same drug to mice that lacked the Mas receptor entirely, it had no effect. This proved that the drug works specifically by engaging the Mas receptor and not through some other random mechanism.
The study also explored how this receptor works on a cellular level. In experiments using human sperm in a dish, adding the activating drug caused a temporary boost in sperm movement, but only at very specific, low concentrations. If the concentration was too high, the benefit disappeared. The drug also influenced how sperm reacted to calcium, a key signal for fertility, and reduced the number of sperm that reacted prematurely. In the diabetic mice, the treatment appeared to work through a different set of chemical signals than those typically associated with cell survival, suggesting the body uses multiple pathways to repair damage. The researchers were careful to note that while the results in mice were promising, the findings in humans were exploratory and based on small sample sizes. They did not claim to have solved the problem of male infertility or to have proven a specific molecular mechanism for how the drug protects the testes.
Ultimately, this research paints a clearer picture of how the body regulates male fertility. It confirms that the Mas receptor is a key player in the production of healthy sperm and that its absence or blockage leads to reproductive issues. The study suggests that activating this receptor with a drug like AVE0991 could offer a way to protect the testes from the damaging effects of diabetes, potentially preserving fertility in men with this condition. While the work does not yet provide a ready-made treatment for humans, it identifies a specific biological target that could be developed into future therapies. The findings highlight that the same chemical systems that keep our blood pressure in check are also quietly working to ensure the next generation of life can begin.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.